Key Stats for Novo Nordisk Stock
- Pre-market Price Change for Novo Nordisk stock: 6%
- $NVO Share Price as of Dec. 22: $48
- 52-Week High: $94
- $NVO Stock Price Target: $53
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Novo Nordisk (NVO) stock jumped 6% today after the FDA approved the world’s first oral GLP-1 pill for weight management.
The Wegovy pill will be available at pharmacies and through select telehealth providers starting early January 2026, priced at $149 per month, with savings offers.
This is a significant milestone for Novo Nordisk. The pill delivers similar weight-loss results to the injectable version of Wegovy, with patients losing an average of 16.6% of their body weight in clinical trials.
Even more impressive, one in three people lost 20% or more of their weight. The pill gives patients a convenient once-daily option instead of weekly injections.
The approval comes at a crucial time for NVO stock. The company has faced a tough year marked by supply chain issues, board conflicts, and pressure from rival Eli Lilly.
Novo also recently lost a bidding war for obesity drug developer Metsera to Pfizer, which paid $10 billion to secure the asset.
Despite these challenges, today’s FDA approval gives Novo a significant competitive edge. No other oral GLP-1 treatment currently matches the weight loss achieved by Wegovy.
The company also struck a deal with the Trump administration to make the pill available through TrumpRx, the direct-to-consumer website, at the same $149 price point for cash-paying patients.
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>
What the Market Is Telling Us About Novo Nordisk Stock
The market’s strong reaction shows investors believe the oral pill can reignite growth for NVO stock. Being first to market with an oral GLP-1 for obesity gives Novo a head start over Eli Lilly, which has been gaining market share with its competing treatments.
CEO Mike Doustdar emphasized the breakthrough nature of this approval: “The pill is here. With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection.”
The pill addresses a key barrier for many patients who prefer not to use injectable medications. By offering the same weight-loss results in pill form, Novo opens the market to a broader patient base.
The company has also submitted the oral pill for approval in Europe and other markets during the second half of 2025.
However, investors should remember that Novo still faces headwinds. The company’s recent loss in the Metsera bidding war was a setback in building out its obesity pipeline.
Pfizer ultimately won with an $86.25-per-share offer after the FTC raised antitrust concerns about Novo’s bid. A source close to Novo said their final bid represented Metsera’s “maximum value” and that losing the deal wasn’t critical to their strategy.
The 6% gain helps recover some of NVO stock’s losses this year, but shares remain down by more than 50% from their 52-week high.
The FDA approval of the Wegovy pill gives investors a reason to be optimistic about the company’s ability to compete in the growing weight-loss drug market, which analysts estimate could reach $150 billion by the early 2030s.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Novo Nordisk Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
